Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Related Citations for PubMed (Select 22555108)

1.

TRAIL-R3-related apoptosis: epigenetic and expression analyses in women with ovarian neoplasia.

Braga Lda C, Alvares da Silva Ramos AP, Traiman P, Silva LM, Lopes da Silva-Filho A.

Gynecol Oncol. 2012 Aug;126(2):268-73. doi: 10.1016/j.ygyno.2012.04.038. Epub 2012 Apr 30.

PMID:
22555108
2.

Epigenetic and expression analysis of TRAIL-R2 and BCL2: on the TRAIL to knowledge of apoptosis in ovarian tumors.

Braga Lda C, Silva LM, Piedade JB, Traiman P, da Silva Filho AL.

Arch Gynecol Obstet. 2014 May;289(5):1061-9. doi: 10.1007/s00404-013-3060-0. Epub 2013 Nov 5.

PMID:
24190693
3.

Single CpG island methylation is not sufficient to maintain the silenced expression of CASPASE-8 apoptosis-related gene among women with epithelial ovarian cancer.

Braga Lda C, Silva LM, Ramos AP, Piedade JB, Vidigal PV, Traiman P, da Silva Filho AL.

Biomed Pharmacother. 2014 Feb;68(1):87-91. doi: 10.1016/j.biopha.2013.12.004. Epub 2013 Dec 24.

PMID:
24412083
4.

Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression.

Keita M, Wang ZQ, Pelletier JF, Bachvarova M, Plante M, Gregoire J, Renaud MC, Mes-Masson AM, Paquet ÉR, Bachvarov D.

Gynecol Oncol. 2013 Feb;128(2):356-63. doi: 10.1016/j.ygyno.2012.11.036. Epub 2012 Dec 2.

PMID:
23219462
5.

High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.

Chamuleau ME, Ossenkoppele GJ, van Rhenen A, van Dreunen L, Jirka SM, Zevenbergen A, Schuurhuis GJ, van de Loosdrecht AA.

Leuk Res. 2011 Jun;35(6):741-9. doi: 10.1016/j.leukres.2010.12.032. Epub 2011 Feb 1.

6.

The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation.

Sernbo S, Gustavsson E, Brennan DJ, Gallagher WM, Rexhepaj E, Rydnert F, Jirström K, Borrebaeck CA, Ek S.

BMC Cancer. 2011 Sep 24;11:405. doi: 10.1186/1471-2407-11-405.

7.

[Expression of hSef and FGF-2 in epithelial ovarian tumor].

Feng QL, Shi HR, Qiao LJ, Zhao J.

Zhonghua Zhong Liu Za Zhi. 2011 Oct;33(10):770-4. Chinese.

PMID:
22335910
8.

Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.

Mercier PL, Bachvarova M, Plante M, Gregoire J, Renaud MC, Ghani K, Têtu B, Bairati I, Bachvarov D.

Mol Oncol. 2011 Oct;5(5):438-53. doi: 10.1016/j.molonc.2011.07.003. Epub 2011 Jul 26.

9.

Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers.

Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, Rahmatpanah F, Shi H, Ng SW, Yan PS, Nephew KP, Brown R, Huang TH.

Clin Cancer Res. 2002 Jul;8(7):2246-52.

10.

The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer.

Czekierdowski A, Czekierdowska S, Wielgos M, Smolen A, Kaminski P, Kotarski J.

Neuro Endocrinol Lett. 2006 Jun;27(3):381-6.

PMID:
16816827
11.

Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.

Kikuchi R, Tsuda H, Kanai Y, Kasamatsu T, Sengoku K, Hirohashi S, Inazawa J, Imoto I.

Cancer Res. 2007 Aug 1;67(15):7095-105.

12.

Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells.

Izutsu N, Maesawa C, Shibazaki M, Oikawa H, Shoji T, Sugiyama T, Masuda T.

Int J Oncol. 2008 Jun;32(6):1227-35.

PMID:
18497984
13.

Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer.

Bondurant AE, Huang Z, Whitaker RS, Simel LR, Berchuck A, Murphy SK.

Gynecol Oncol. 2011 Dec;123(3):581-7. doi: 10.1016/j.ygyno.2011.08.029. Epub 2011 Sep 28.

PMID:
21955482
14.

Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance.

Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins AC, Li Y.

Gynecol Oncol. 2007 Jun;105(3):695-702. Epub 2007 Mar 21.

PMID:
17368732
15.

[Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].

Sun LX, Wu Y, Han HQ, Wang QH.

Ai Zheng. 2003 Jan;22(1):58-61. Chinese.

PMID:
12561438
16.

POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.

Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D.

Gynecol Oncol. 2014 Feb;132(2):334-42. doi: 10.1016/j.ygyno.2013.12.021. Epub 2013 Dec 22.

PMID:
24368280
17.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site.

Ruiz de Almodóvar C, Ruiz-Ruiz C, Rodríguez A, Ortiz-Ferrón G, Redondo JM, López-Rivas A.

J Biol Chem. 2004 Feb 6;279(6):4093-101. Epub 2003 Nov 17.

18.

Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.

Choi YL, Kim J, Kwon MJ, Choi JS, Kim TJ, Bae DS, Koh SS, In YH, Park YW, Kim SH, Ahn G, Shin YK.

Histol Histopathol. 2007 Nov;22(11):1185-95.

PMID:
17647191
19.

[Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma].

Zhang MZ, Qiao YH, Suo ZH.

Zhonghua Zhong Liu Za Zhi. 2008 Nov;30(11):848-52. Chinese.

PMID:
19173831
20.

Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers.

Gloss BS, Patterson KI, Barton CA, Gonzalez M, Scurry JP, Hacker NF, Sutherland RL, O'Brien PM, Clark SJ.

Cancer Lett. 2012 May 1;318(1):76-85. doi: 10.1016/j.canlet.2011.12.003. Epub 2011 Dec 9.

PMID:
22155104
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk